Compare PD & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PD | VRDN |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | 1155 | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 2.1B |
| IPO Year | 2019 | 2014 |
| Metric | PD | VRDN |
|---|---|---|
| Price | $13.97 | $21.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $12.63 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 1.5M | 1.1M |
| Earning Date | 05-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 416.95 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $492,546,000.00 | $5,706,000.00 |
| Revenue This Year | $3.58 | $13.73 |
| Revenue Next Year | $2.88 | $279.00 |
| P/E Ratio | $76.00 | ★ N/A |
| Revenue Growth | ★ 5.36 | N/A |
| 52 Week Low | $5.70 | $13.18 |
| 52 Week High | $16.91 | $34.29 |
| Indicator | PD | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 61.48 | 46.44 |
| Support Level | $12.78 | $21.40 |
| Resistance Level | $14.43 | $23.84 |
| Average True Range (ATR) | 0.51 | 0.88 |
| MACD | -0.03 | -0.24 |
| Stochastic Oscillator | 58.68 | 28.87 |
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.